Treatment Cohort Arm
Micrometastasis Clearance
92.8%
Tumor eradication
Primed CD8+ Expansion
18.4x
Neoantigen specific
PD-1 Receptor Blockade
94.5%
Exhaustion suppressed
Recurrence Hazard Ratio
0.56
44% risk reduction
3-Yr Recurrence-Free Surv.
74.2%
vs 55.6% Keytruda mono